Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†

Autor: Julien Mazieres, P.-J. Souquet, G. Jeannin, J. Tredaniel, P. Dumont, H. Le Caer, Gérard Zalcman, F. Vaylet, L. Petit, C. Dayen, B. Coudert, Virginie Westeel, M. Poudenx, P. Barre, F. Goutorbe, H. Monnot, P. Deguiral, C. Raspaud, S. Schneider, P. Chatellain, A. Lavole, A. Dixmier, D. Coëtmeur, D. Moro-Sibilot, J. Dauba, R. Gervais, E. Pichon, H. Berard, J.P. Oster, Olivier Molinier, Pierre-Jean Lamy, P. Mourlanette, Franck Morin, Fabrice Barlesi, Luc Thiberville, M. Zaegel, Yves Martinet, M. Derollez, J-P. Duhamel, Elisabeth Quoix, P. Romand, A. Renault, A. Langlais, H. Laize, Pascal Foucher, Debra S. Herman, H. Doubre, Jean-Louis Pujol, S. Dehette, J-P. Gury, N. Baize, P. Fournel

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2015, 26 (5), pp.908-914. ⟨10.1093/annonc/mdv065⟩
Annals of Oncology, 2015, 26 (5), pp.908-914. ⟨10.1093/annonc/mdv065⟩

IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. Background This randomized phase II–III trial sought to evaluate the efficacy and safety of adding be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27d2b0ccdfe0fafac0c9038afd82630e
https://hal.umontpellier.fr/hal-02121126

Long-term survivors of small-cell lung cancer (SCLC): A French multicenter study

Autor: Ranfaing E, D. Moro, Bernard Milleron, Elisabeth Brambilla, Alain Depierre, D Anthoine, G Garnier, Pierre Fournel, J P Kleisbauer, P. Jacoulet, Frédérique Capron, Alain Rivière, E. Quoix, J P Leclerc, F Massin, Bernard Lebeau, M Zaegel, Jean-Jacques Lafitte

Publikováno v: Annals of Oncology. 8:1009-1014

Summary Background The aim of this study was to analyze SCLC patients beyond 30 months, particularly their outcome, their way of life, and factors which could influence relapses, second-primary cancers and death. Patients and methods Between January

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::904c33600658701836adae0bf29a7626
https://doi.org/10.1023/a:1008287922285

Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Française

Autor: P, Jacoulet, A, Depierre, D, Moro, A, Rivière, B, Milleron, E, Quoix, E, Ranfaing, D, Anthoine, J J, Lafitte, B, Lebeau, J P, Kleisbauer, F, Massin, P, Fournel, M, Zaegel, J P, Leclerc, G, Garnier, E, Brambilla, F, Capron

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 8(10)

The aim of this study was to analyze SCLC patients beyond 30 months, particularly their outcome, their way of life, and factors which could influence relapses, second-primary cancers and death.Between January 1986 and May 1995, 263 SCLC patients who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6f51ffb15a0dfcb744be37ba7cf88e3b
https://pubmed.ncbi.nlm.nih.gov/9402175

Risk of Major Bleeding in Cancer Patients Receiving Chemotherapy

Autor: J. Kim, M. Naghiby Sustany, Connie Chen, A. Ruiz-Valdepeñas, S. Perrin, A. Chaslerie, C. Terret, Nichole Young-Lin, K. Kim, H. Hoeffkes, M. Carvalho-Verlinde, L.C. Park, M. Kroez, Omneya Hassanain, T. van Gelder, L. Xiong, T.K. Kiet, S. Dacosta Byfield, J. Goswami, C.K. Bose, H. Bourgeois, J. Metges, A. Fani Pakdel, L. Marelli, Y. Lou, D.S. Kapp, S. Bercier, E. Lugatti, A. Costantini, R.P. Riechelmann, S. Patel, Q. Dong, J. Finek, H. Ghazal, K. Chatterjee, B. Chatterjee, G. Fasola, Z. Hu, E. Minvielle, S. J. Mukhopadhyay, W.K. Redekop, S. Abouelnaga, J.K. Chan, P. Pronzato, R. Laporta, J.H. Zong, Gary H. Lyman, M. Ghielmini, D.H.S. Brundel, A. Zimmermann, Jun Suk Kim, R. Barroso-Sousa, J. Ma, P.M. Hoff, W. Baumann, S. Banerjee, U.R. Kleeberg, François Lemare, F.K. Tauchert, M. Hipp, C. Atchison, Y. Tang, J. Menis, C. Locher, B. Cantos, S. Nawrocki, L. Zhang, E. De Droogh, M. Irwin, P. Das, G.A.M.S. (Guus) van Dongen, S.K. Sarkar, A. Olaverri Hernandez, R.W.F. van Leeuwen, G. Hebert, P. Martin Martorell, F.G.A. Jansman, A. Fourcade, B.K. Mohanti, H.J. Conter, G. Streich, J. Piquet, G. Iacono, P. Bycott, C. Bighin, C. Pedrazzani, A. Carrato, JA Santiago Crespo, A. Baitar, S. Pizzolitto, D. Debieuvre, O. Gunther, T. Collon, E. Jaeger, B. Han, I. Duran, L. Testa, M. Lambertini, J. Gutsch, J.W. Lee, D. Galdermans, S. Negrier, D. Mauri, N. Nakayama, K. Veerabudun, T. Teague, G. Spahn, M. Jofre-Bonet, Z. Brixi, M. Maglakelidze, H. Li, R. Ferreira, H. Ryu, R. Zaim, L.H. Martinez, D. Lorusso, R. Cardiga, J. Liu, F. Poggio, C. Herbstreit, M. Rezazadeh, R. von Moos, J. Pivette, J. Mebis, F. Ceia, A. Ohtsu, A. Le Thuaut, F. Blanchon, M. Weber, V. Tozzi, F. van Fraeyenhove, A.C.R.C. Ferrari, D-W. Ye, D. Pastorelli, M. Gaiardo, L. Gurrieri, S. Al-Batran, R. Eckert, A. Happe, L. Del Mastro, M.V. Karamouzis, W. Hwu, R. Li, A. Zhou, V. Petry Helena, C. Neef, J.R. Puyol, M. Laurent, C. Ortega Ruiperez, G. D'Addario, C. Fonseca, R. de Bree, M. Zaegel, M. Provencio Pulla, Sabine Tejpar, G. Rosti, L. De Fiore, Y.J. Choi, M. Fink, E. Terpos, M. Precivale, T.K. Takahashi, Tetsuji Takayama, David M. Burger, J. Feliu, M. Debus, K. Tamas, C.A. Uyl-de Groot, A. Voigt, C. Fu, E. Molinas, C. Maximiano, L. Eckert, C.O. Ruiperez, D. Bertwistle, T. Mossman, A. De Maria, C.T. Carvalho, V. Raina, C. Guillen-Ponce, H. Matthes, Arijit Mukhopadhyay, M. Muñoz Sanchez, G.M. Bariani, D. Pérez Callejo, J. Lebreton, D. Hoth, Florence Netzer, E. Liuu, A. Leitão, P. Ussetti, A. Gu, A.C. Palozzo, N. Maniadakis, Sameera Ezzat, L.G. Fonseca, E. Bria, A.T. Cohen, E.J. Batagelj, T. Yoshino, M. Sabry, A. Jirillo, N. Papadopolous, N. Cherny, I. Amanam, M. Tettamanti, J. Axtner, M.S. Mano, P. Rescigno, D. Conter, T. Tanase, S.K. Mondal, M. Blanco Villalba, Sung Heon Kim, G. Lanzetta, M. Palka, F. Schad, A. Small, D. Lueftner, R. Arai, O. Mora, Jayasri Basak, S. Piau, A. Mahmood, M. Mendez Garcia, D. Romeira, A.M. Martins, S. Schmitz, Y. Huang, S. Imbevaro, N. Marschner, Svs Deo, Ron H.J. Mathijssen, E. Meszko, F. Lobo, E. Ferrat, F. Martin, Johan Vansteenkiste, M. Molina-Garido, M.P. Mak, R.E. Buschmann-Maiworm, I. Bourlaud, A. Bedikian, Ahmad S. Alfaar, R. De Paula Costa, T. Denda, P. Anderson, J. Quidde, J. Lake, Ajay Gogia, M. Grivaux, S-H Lee, S. Vlassak, M.P. Bramajo, C. El Kouri, P. Quadri, Young-Suk Park, P. Donny, S. Gangopadhyay, A. Follador, Francesca Valent, W.S. Dai, E. Almagro Casado, S. Giraudi, J. Guo, A. Pini, M.P. Trojniak, R. Curca, M. Proença, Mohamed Kamal, M. Le Poulain-Doubliez, A. D'Alonzo, J. Pereira, N. Jokhadze, M. Di Maio, H. Hoefeler, C. Rossetto, C. Reyes, C. Hamada, E. Paillaud, Josep Tabernero, R. Gagua, C. Attali, H. Sleeboom, A. Vandebroek, G. Hechmati, J. Body, R. Wei, S. Culine, Fortunato Ciardiello, Robert A. Wolff, R. Hofheinz, P. Caillet, M.L. Gomez, Michel Ducreux, M. Rucinska, P. Hwu, A. Bahl, W. Chang, J. Douillard, Hirofumi Fujii, A. Kieszkowska-Grudny, M. Alface, F. Grude, B.J. Monk, F. Canouï-Poitrine, Nootan Kumar Shukla, A. Levaggi, D. Schrijvers, M. Urbanski, S. Rauh, S. Bastuji-Garin

Publikováno v: Annals of Oncology. 23:ix447

Cancer patients receiving chemotherapy are at increased risk of venous thromboembolism (VTE). The presence of cancer and anticoagulant use are risk factors for bleeding, yet data on bleeding risk are limited in these patients. This analysis evaluated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65631e191932d84667ee1fa2bb6bf709
https://doi.org/10.1093/annonc/mds410

IFCT-0504 trial: Mucinous (M) and nonmucinous (NM) cytologic subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC) by erlotinib (E) or carboplatin/paclitaxel (C/P)

Autor: L. Moreau, Isabelle Monnet, Laurence Baudrin, Marie Wislez, Jacques Cadranel, Fabrice Barlesi, J. Duhamel, G. Zalcman, Laurence Bigay-Game, E. Quoix, Radj Gervais, Pierre-Jean Souquet, Patrick Merle, G. Oliviero, Virginie Westeel, Franck Morin, Sylvie Friard, Luc Thiberville, D. Moro-Sibilot, M. Zaegel

Publikováno v: Journal of Clinical Oncology. 29:7521-7521

7521 Background: First-line EGFR-TKI in advanced BAC yielded a 2.9 to 4-month PFS in Phase II trials. We have suggested that EGFR-TKI had a reduced activity in M-BAC but that C/P and pemetrexed cou...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::247ed3497e407cde4dc471c424e9e54d
https://doi.org/10.1200/jco.2011.29.15_suppl.7521